Shield Therapeutics (LON:STX) Shares Down 10.2% – Here’s What Happened

Shield Therapeutics plc (LON:STX)’s stock price was down 10.2% during mid-day trading on Thursday . The company traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.38 ($0.03). Approximately 2,388,393 shares changed hands during mid-day trading, a decline of 4% from the average daily volume of 2,478,849 shares. The stock had previously closed at GBX 2.65 ($0.04).

Shield Therapeutics Stock Performance

The company has a market cap of £23.19 million, a P/E ratio of -0.61 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a 50 day moving average price of GBX 3.11 and a 200-day moving average price of GBX 3.09.

Insider Activity

In other news, insider Anders Lundstrom acquired 575,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($30,581.04). 62.16% of the stock is owned by insiders.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.